x
ServiziMenu principaleHome
You are here: Home > Events > Future Events > UNIMI-ESO Post-graduate Course on Biliary Tract Cancer and Neuroendocrine Tumors
Print

UNIMI-ESO Post-graduate Course on Biliary Tract Cancer and Neuroendocrine Tumors

15.04.2019  -  18.04.2019

Milan, Italy

ADVANCED COURSES & SEMINARS

Neuroendocrine tumors

Description




Scientific Coordinator:
V. Mazzaferro, IT - F. De Braud
, IT


The University of Milan, Italy, in close collaboration with the European School of Oncology, will organise the first post-graduate course on biliary tract cancer and neuroendocrine tumors.

This programme is addressed to an international audience of clinical oncologists, surgeons, pathologists, gastroenterologists, radiologists, radiotherapists, interested in advancing their knowledge and skills on the clinical management of biliary tract cancer and neuroendocrine tumors, in a multidisciplinary context. It will last four days for a total of 30 teaching hours and the official language will be English.

We are aware that “networking” is the keyword in improving quality of care of rare cancers.
Both ESO and the University of Milan are involved as associated partners in EURACAN, the European Reference Network on rare adult solid cancers. Thus, this educational effort aims to reinforce the collaboration among oncologists of different countries who are already involved in EURACAN, or in networks related to EURACAN, or willing to be part of it in the near future.

Admission to the course will be on competitive application only. Attendance is limited to 30 participants.

LEARNING OBJECTIVES
• To provide an overview of current multidisciplinary state-of-the-art treatments of biliary tract cancer and neuroendocrine tumors
• To discuss relevant clinical cases on a multidisciplinary basis
• To establish connections for future distance clinical mentoring/tutoring/networking

The post-graduate course is a Università degli Studi di Milano-ESO joint initiative
                     
Held in collaboration with         In the framework of
 INT                



General information

ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
Marina Fregonese
email: mfregonese@eso.net
phone +39 02 23902106

VENUE
University of Milan
Room InfoGiure
Via Festa del Perdono, 3/7
Milan, IT

ACCREDITATION
Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising Secretariat.

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

Application

PARTICIPANT’S PROFILE
Medical degree
Current involvement in clinical activities in oncology (with preference to rare cancers).

REGISTRATION FEE
The registration fee must be paid
by accepted candidate after the selection procedure.
€ 316 (tax included)

ADMISSSION/REGISTRATION
Admission to the course will be on competitive application only. Attendance is limited to 30 participants.

Applications will be collected by University of Milan via website www.unimi.it, from February 15, 2019.

It is already possible to complete a pre-application from now (at the top of this page).

The pre-registration procedures on the ESO website are intended to help participants with the submission of the candidature to the University of Milan. The applications must be uploaded on the University website within the set deadline.

All applicants are requested to upload on the UNIMI website the following documents:

1. Curriculum vitae (in English)
2. Brief description of professional background (in English)

Only non-italian participants (*):
3. Copy of degree/diploma
4. Official translation in Italian of the degree/diploma, authenticated by the authorities of the Country in which they were issued
5. Diploma Supplement (non Italian EU citizens only) - see further information below
6. Statement of validity (non Italian – non EU citizens only) - see further information below

(5) European Countries that have adhered to the so-called “Bologna Process” have also committed to produce, alongside their own higher education qualifications, an extra document known as the Diploma Supplement (DS). The DS is not a further qualification, but a particular certification produced following a template which was agreed upon by the three principal international organizations of European breadth (The Council of Europe, UNESCO – Europe region, European Union). The European DS model envisages that it be drafted in two or more languages (the national language of the Country in question and at least one commonly-spoken foreign language, such as English), and that it provide a whole list of very detailed information. The information is grouped into 8 categories, which run from the personal details of the qualification holder, to the level of the qualification itself, the curriculum (list of subjects and, if possible, their principal contents), the rights it bestows (utilization for further studies or in the workplace), to the type of issuing institution, and to an abbreviated description of the higher education system it belongs to. In as much as it reconstructs in an analytical, precise and transparent way the educational itinerary that led to a specific qualification, the DS is very useful tool and of great help for a correct evaluation of the course and qualification it refers to. It is therefore believed that the DS can facilitate the procedures of academic and professional qualification recognition.

(6) The Statement of validity is a document of transparency, written in Italian, that gives information on a specific qualification earned abroad and on its value in the issuing Country (the official character or otherwise of the issuing institution, requirements for access to the relevant study course, length of course, etc.). Such a Statement is produced by the foreign Italian diplomatic authorities (Embassies, Consulates) of territorial reference: territorial reference is defined as the Italian diplomatic authority closest to the city where the institution that awarded the qualification is located. All the documents to be presented in order to obtain the Statement of Validity must be requested at the relevant Italian diplomatic authority for the release of the same (Embassies/Consulates). The release of the Statement of Validity does not mean that the foreign qualification will be recognised in Italy, and indeed the Italian diplomatic representations have no authority as regards the recognition of Italian qualifications, therefore any comparison/equalization made inside the document is not binding in any way on the legally authorized institutions which perform recognition procedures. Indeed, it should be remembered that “the request for the Statement of Validity, all things considered, is equivalent to a mere established procedure, which does not exclude the authority-duty of the Administration to perform its own autonomous evaluations even when the relevant diplomatic authority has not produced the requested statement or has produced it in generic or insufficient terms” (consult Council of State Sentence n. 4613 of 4/9/07).

Programme

15 April

BILIARY TRACT CANCER: ELEMENTS FOR TREATMENT PLANNING
8:30   Registration, Introduction and Course overview
V. Mazzaferro, IT
9:30   Epidemiology, Risk-factors and Clinical presentations
D. Alvaro, IT
10:30   Staging and Imaging
A. Vanzulli, IT
11:30   Assessing liver function, cholestasis and co-morbidites as hierarchic drivers for tumor treatment allocation
V. Mazzaferro/S.Bhoori, IT
12:30   Guidelines for clinical management of Biliary tract cancer
C. Sposito, IT
13:30   Lunch
BILIARY TRACT CANCER: TREATMENT STRATEGIES
14:30   Cholestasis, inflammation, autoimmunity and biliary tract cancer
P. Invernizzi, IT
15:30   Anatomy of the biliary system and implications for treatment
P. Majno, CH
16:30   Principles of curative treatments counting on liver regeneration and (sometimes) liver replacement
V. Mazzaferro, IT
17:30   Pathology and biology spectrum of biliary tract cancers
M. Roncalli, IT

 16 April

9:00   Palliation of cholestasis and palliative procedures
M. Mutignani, IT
10:00   Treatment of Biliary tract cancer in the medical setting:
neoadjuvant, adjuvant and combinations with radiotherapy
F. de Braud, IT
11:00   New tumor targets and immune microenvironment
F. Pietrantonio, IT - M. Droz dit Busset, IT
12:00   Role of Radiation therapy
M. Scorsetti, IT
13:00   Lunch
BILIARY TRACT CANCER
14:30   Tumor Board on Biliary Tract Cancer:
Case discussions, Video demonstrations, Multidisciplinary consensus
C. Sposito, IT - S. Bhoori, IT - F. de Braud, IT - G. Delconte, IT - M. Droz dit Busset, IT - V. Mazzaferro, IT - F. Pietrantonio, IT

17 April

NEUROENDOCRINE TUMORS (NET): A MULTIFACED TUMOR FAMILY
9:00   The spectrum of NET: classification and clinical implications
S. Massironi, IT
10:00   The spectrum of NET: pathology and beyond
M. Milione, IT
11:00   Molecular tumor profiling and biomarkers
D. Ferone, IT
12:00   The support of imaging to diagnosis and staging
A. Vanzulli, IT
13:00   Lunch
NEUROENDOCRINE TUMORS (NET): MULTIFACED TREATMENT STRATEGIES
14:00   Framing treatment strategy: the ENET guidelines
M. Caplin, UK
15:00   Liver mets from NET
V. Mazzaferro, IT
16:00   Non gastro-entero-pancreatic NET
M. Caplin, UK
17:00   Where are we standing and where are we going with Somatostatin analogues
N. Fazio, IT

18 April

9:00   Where are we standing and where are we going with molecular target therapies
F. de Braud, IT
10:00   Novel targets and role of metformine
S. Pusceddu, IT
11:00   Peptide Receptor Radionuclide Therapy (PRRT): an update
A. Singh Bad Berka, DE
12:00   Co-morbidities, syndromes, QoL in NET
S. Bhoori, IT
NEUROENDOCRINE TUMORS (NET)
14:00   Tumor Board on Neuroendocrine tumors
Case discussions, Video demonstrations, Multidisciplinary consensus
S. Bhoori, IT - F. de Braud, IT - M. Caplin, IT - J. Coppa, IT - G. Delconte, IT - V. Mazzaferro, IT - S. Pusceddu, IT - A. Singh, IT - C. Spreafico, IT
17:00   The problem of Rare Cancers and the EU initiatives
P.G. Casali, IT
18:30   End of the Course and CME questionnaire
V. Mazzaferro


Each topic will be discussed in 45 min presentation followed by 15 min discussion.

Case examples will be taken from the National Cancer Institute of Milan series.

Follow us